T

his has been a blockbuster year for federal regulators investigating bribery in the pharmaceutical industry.

Three of the world’s biggest drug companies, along with two smaller companies, agreed to pay a collective $63 million this year to settle allegations that they violated the US Foreign Corrupt Practices Act by bribing doctors and government officials to promote their medicines overseas.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.